

Table 1. Descriptive Statistics for anti-glycan antibody levels in RRMS and control groups^a . A more detailed version of table 3 in Schwarz et. Al including segmentation to patients in relapse vs patients in remission.

| Sugar Ligand | Signal | Total RRMS (n=107) | MS patients in relapse (n=66) | MS patients in remission (n=41) | PPMS (n= 16) | OAD (n= 27) | OND (n = 50) |
|------------------------|-----------------------------|--------------------------|-------------------------------------|---------------------------------------|-------------------|-------------------|---------------------|
| Glc(α1,4)Glc(α) | Median, RFU*10 ⁶ | 10.59 | 11.96 | 9.90 | 8.23 | 6.47 | 1.14 |
| | SD | 8.76 | 9.60 | 8.12 | 6.41 | 6.05 | 6.56 |
| | # p-value (vs RRMS) | | | | | | |
| | * p-value (vs Relapsing MS) | | | 0.14* | 0.25 [#] | 0.06 [#] | <0.001 [#] |
| α-Glc | Median, RFU*10 ⁶ | 8.91 | 11.13 | 8.47 | 6.53 | 6.65 | 2.07 |
| | SD | 9.88 | 10.90 | 9.08 | 13.40 | 6.28 | 5.62 |
| | # p-value (vs RRMS) | | | | | | |
| | * p-value (vs Relapsing MS) | | | 0.13* | 1 [#] | 0.36 [#] | <0.001 [#] |
| α-Rha | Median, RFU*10 ⁶ | 22.55 | 20.44 | 23.36 | 33.05 | 18.69 | 10.15 |
| | SD | 15.57 | 13.70 | 16.59 | 18.38 | 12.84 | 9.08 |
| | # p-value (vs RRMS) | | | | | | |
| | * p-value (vs Relapsing MS) | | | 0.27* | 0.3 [#] | 0.41 [#] | <0.001 [#] |
| α-GlcNAc | Median, RFU*10 ⁶ | 17.38 | 17.74 | 16.63 | 13.72 | 12.65 | 4.12 |
| | SD | 10.03 | 8.85 | 10.76 | 9.61 | 8.40 | 8.52 |

| | | | | | | | | |
|--|-----------------------------|--|--|-------|------------------|-------------------|---------------------|--|
| | # p-value (vs RRMS) | | | | | | | |
| | * p-value (vs Relapsing MS) | | | | | | | |
| | | | | 0.78* | 0.8 [#] | 0.07 [#] | <0.001 [#] | |

^aMS, multiple sclerosis; OAD, other autoimmune diseases; OND, other neurological diseases; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.